title: [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
abstract: OBJECTIVE
  To evaluate the effects and safety of the regimen of bortezomib combined with dexamethasone (VD) in the treatment of primary systemic (AL) amyloidosis.
  
  
  METHODS
  Five newly diagnosed AL amyloidosis patients confirmed by renal biopsy with a median of 3 organs involved (3 to 5 organs) were treated by VD regimen for 3 (1-4) cycles.
  
  
  RESULTS
  Among 3 evaluable patients, 1 was in stable condition and 2 had hematologic response (partial remission and complete remission) and organ function improvement. Hematologic responses were rapid (median 1.5 cycles) and median time to organ response was 2 cycles. Three cases were survived and the periods of follow up were 5, 4 and 4 months respectively. The other 2 died 2 and 14 months after diagnosis. The side effects were asthenia, diarrhea, constipation, edema aggravation and fever, all of which were in I grade. No treatment associating death was found.
  
  
  CONCLUSIONS
  VD regimen might be an efficient, rapid effective and safe regimen in the treatment of AL amyloidosis.
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. luliyuan@tom.com
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhao
authors.forename: Li-jin
authors.initials: LJ
authors.lastname: Zeng
authors.forename: Chang
authors.initials: C
authors.lastname: Su
authors.forename: He-hua
authors.initials: HH
authors.lastname: Wang
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D004338:Drug Combinations; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone